Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04710576 · ClinicalTrials.gov registry record · Phase 2

A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)

A Phase 2 study of Chronic Graft Versus Host Disease, sponsored by Syndax Pharmaceuticals.

Active
Registry status
Phase 2
Development phase
241
Enrollment target
20
Study locations

NCT04710576 is a Phase 2 study of Chronic Graft Versus Host Disease that is active but no longer recruiting, run by Syndax Pharmaceuticals. The registered enrollment target is 241 participants, above the 108-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (123% higher). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04710576, a Phase 2 study of Chronic Graft Versus Host Disease, is active but no longer recruiting, sponsored by Syndax Pharmaceuticals.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
241 participants
Enrollment target
20
Study locations

Study Summary

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

Conditions Studied

Chronic Graft Versus Host Disease

Interventions

  • DRUG Axatilimab

Study Locations (20)

Florida

  • University of Florida (UF) - Gainesville
  • Mayo Clinic - Jacksonville - Jacksonville
  • University of Miami - Miami
  • AdventHealth Orlando - Orlando
  • Moffitt - Tampa

California

  • City of Hope - Duarte
  • University of Southern California Norris Comprehensive Cancer Center - Los Angeles
  • University of California, Los Angeles (UCLA) - Medical Center - Los Angeles
  • Stanford Cancer Center - Stanford

Alabama

  • University of Alabama at Birmingham - Children's of Alabama - Birmingham
  • University of Alabama at Birmingham - Birmingham

Georgia

  • Emory University - Atlanta
  • Northside Hospital - Atlanta

Indiana

  • Indiana University Health Melvin and Bren Simon Cancer Center - Indianapolis
  • Franciscan Health Indianapolis - Indianapolis

District of Columbia

  • Children's National Medical Center - Washington D.C.

Illinois

  • The University of Chicago Medical Center (UCMC) - Chicago

Louisiana

  • Tulane University Medical Center - New Orleans

Trial Details

FieldValue
Enrollment Target 241 participants
Start Date 2021-03-04
Est. Completion 2027-09
Phase Phase 2

Sponsor

Syndax Pharmaceuticals

25 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04710576

The ClinicalTrials.gov registry entry for NCT04710576 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 241 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 108-participant average among 30 other Chronic Graft Versus Host Disease trials with a reported enrollment target (123% higher). The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Graft Versus Host Disease appearing as the primary indexed condition, and to 1 intervention - of which Axatilimab is the first listed.

NCT04710576 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, California, Alabama.

Frequently Asked Questions

What is clinical trial NCT04710576 about?

NCT04710576 is a clinical study titled "A Study of Axatilimab at 3 Different Doses in Participants With Chronic Graft Versus Host Disease (cGVHD)". This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractory active chronic graft versus host disease (cGVHD) who have received at least 2 prior lines of systemic therapy.

What is the current status of trial NCT04710576?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 241 participants. The study started on 2021-03-04. Estimated completion is 2027-09.

What conditions does trial NCT04710576 study?

This clinical trial studies the following conditions: Chronic Graft Versus Host Disease.

What interventions are being tested in trial NCT04710576?

The interventions under investigation include: Axatilimab (DRUG).

Who is sponsoring clinical trial NCT04710576?

This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04710576 being conducted?

This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Graft Versus Host Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Graft Versus Host Disease

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.